This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Ms Gollust and colleagues¹ provide evidence that direct-to-consumer marketing of genetic information can mislead consumers and leave them susceptible to manipulation.

Direct-to-consumer advertising, however, has proven to be effective in selected settings, and a blanket proscription of this potentially useful tool is not warranted. For example, the Dor Yesharim program of premarital screening has functioned within the Jewish Orthodox community for more than 2 decades.² This anonymous testing program was designed by community activists and has incorporated unique cultural factors that have enabled it to screen more than 100 000 participants since 1977. Following partner selection by their families, young men and women in their teens or early twenties are tested and assigned a number. Neither they, their prospective partners, nor the program staff are given specific results of the 8 most common disorders prevalent in this population; instead, the numbers are matched at a central location resulting . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Direct-to-Consumer Advertising of Genetic Testing
Sarah E. Gollust, Sara Chandros Hull, and Benjamin Wilfond
JAMA. 2003;289(1):46.
EXTRACT | FULL TEXT  

Limitations of Direct-to-Consumer Advertising for Clinical Genetic Testing
Sarah E. Gollust, Sara Chandros Hull, and Benjamin S. Wilfond
JAMA. 2002;288(14):1762-1767.
ABSTRACT | FULL TEXT